Spots Global Cancer Trial Database for Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
Official Title: A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer
Study ID: NCT00958971
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Comprehensive Blood and Cancer Center Dept CBCC (3), Bakersfield, California, United States
Tower Cancer Research, Beverly Hills, California, United States
UCLA/ University of California Los Angeles Div. of Hematology/Oncology, Los Angeles, California, United States
Cancer Care Associates Medical Group Dept. of CCA, Redondo Beach, California, United States
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
Florida Cancer Specialists Dept.of FloridaCancerSpec. (2), Fort Myers, Florida, United States
Kansas City Cancer Center KCCC (3), Overland Park, Kansas, United States
Associates in Oncology/Hematology, P.C., Rockville, Maryland, United States
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
UNC/ Lineberger Comprehensive Cancer Center Dept. of Linberger Cancer Ctr, Chapel Hill, North Carolina, United States
Northwest Cancer Specialists Northwest Office (2), Portland, Oregon, United States
Texas Oncology, P.A. Dept. of Texas Oncology, Bedford, Texas, United States
Texas Oncology, P.A. Austin, Dallas, Texas, United States
Texas Oncology, P.A. Presbyterian Hospital, Dallas, Texas, United States
Texas Oncology, P.A. Texas Oncology - Sammons, Dallas, Texas, United States
Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, United States
Fairfax Northern Virginia Hematology Oncology Fairfax NVH, Fairfax, Virginia, United States
Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, United States
Novartis Investigative Site, Edmonton, Alberta, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Helsinki, , Finland
Novartis Investigative Site, Lyon Cedex, , France
Novartis Investigative Site, Saint-Herblain Cédex, , France
Novartis Investigative Site, Toulouse Cedex 3, , France
Novartis Investigative Site, Villejuif Cedex, , France
Novartis Investigative Site, Cuneo, CN, Italy
Novartis Investigative Site, Cremona, CR, Italy
Novartis Investigative Site, Parma, PR, Italy
Novartis Investigative Site, Candiolo, TO, Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Negrar, , Italy
Novartis Investigative Site, Barcelona, Cataluña, Spain
Novartis Investigative Site, Lleida, Cataluña, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Glasgow, , United Kingdom
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, London, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
